The Clinical Usefulness of Serum PSA and PSAD in BPH.
- Author:
Jong Ki KIM
1
;
Bong Suk SHIM
Author Information
1. Department of Urology, College of Medicine, Ewha Womans University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
BPH;
PSA;
PSAD
- MeSH:
Biopsy;
Humans;
Inflammation;
Prostatic Neoplasms
- From:Korean Journal of Urology
1995;36(10):1071-1075
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We have reviewed the records of 126 patients with BPH under the assumption that the increase in serum PSA varies depending on the volume, the acute inflammation and the different histologic types. The results are as follows; 1.The PSA and PSAD excluding the 8 patients with acute inflammation were 3.55+/-2.569 and 0.084+/-0.73 in the mixed type, 2.644+/-2.573 and 0.11+/-0.16 in the stromal predominant type, and 2.847+/-0.73 and 0.71+/-0.34 in the glandular predominant type. (P=0.033, 0.054, respectively) 2.The PSA and PSAD were 21.481+/-9.582, 0.312+/-0.143 in the 8 patients with acute inflammation and 3.19+/-2.539 , 0.117+/-0.158 in the 118 patients without inflammation(P=0.000, 0.000, respectively). 3.Of the 35 patients with PSA> 4.0ng/ml, the PSAD of 27 patients, excluding the eight with acute inflammation, and the PSAD of 91 patients who were 4ng/ml and below were 0.11+/-0.058 and 0.059+/-0.045 respectively (P=0.000). Additionally the PSAD of the 25 patients with 4.0ng/ ml=PSA10.0ng/dl and of the 91 patients with 4.0ng/ml and below were 0.11+/-0.041 and 0. 059+/-0.045, respectively ( P=0.000). In view of the results, it cannot be determined that PSAD is more effective in foreseeing the histologic types of BPH than PSA and we cannot recommend the use of PSAD as a substitute for biopsy in the case of increased PSA in predicting and differentiating prostatic cancer.
